Five children in Surat were hospitalized after mistakenly receiving a diabetes drug instead of fever medicine during a government immunization drive on September 23. Authorities have suspended the health worker responsible and are conducting an investigation. The incident highlights critical gaps in safety protocols within public health distribution systems.
A medical oversight during a government immunization drive in Surat, Gujarat, has led to the hospitalization of five children and a subsequent administrative crackdown. On September 23, during the 'Mamta Diwas' program, children at the Palsana-01 sub-center were administered Glimepiride 2 mg, a medication primarily used for blood sugar management in diabetes patients, instead of the intended paracetamol for post-vaccination fever.
The administration of the incorrect drug resulted in a rapid decline in the health of the children, including infants as young as three-and-a-half months old. By September 24, all five children were admitted to Pediatric Intensive Care Units. According to state officials, the children have since stabilized following emergency medical intervention. Gujarat Health Minister Prafull Pansheriya described the incident as a case of significant professional negligence.
Following the event, the Surat district health authorities took disciplinary action against the personnel involved. Induben Ratilal Chaudhary, a Class-3 health worker, has been suspended with immediate effect. Under the suspension terms, she is restricted to reporting to the Dangarapada Primary Health Centre and is barred from taking on other employment during the inquiry period. The government has initiated a departmental investigation to understand how the diabetes medication was stored and distributed alongside standard post-vaccination supplies.
For the healthcare sector and public administration, this incident underscores the risks inherent in manual drug distribution and the critical need for robust inventory management. Similar incidents often prompt government bodies to re-evaluate their drug procurement, labeling, and staff training protocols to prevent such medication errors. Investors and observers of the public health space monitor these events as they often lead to policy shifts, stricter oversight of medical supply chains, and changes in how essential drugs are handled at the grassroots level. The primary monitorable moving forward will be the findings of the departmental inquiry and any new safety measures implemented to ensure medication accuracy during future government health drives.